Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients
The clinical trial sponsored by Charite University aims to evaluate the efficacy of Simvastatin in reducing cognitive decline in patients with Mild Cognitive Impairment (MCI), a precursor to Alzheimer's disease. If successful, this study could position Simvastatin as a potential preventive treatment for Alzheimer's, tapping into a significant market given the rising prevalence of dementia globally. The competitive landscape includes other anti-dementia therapies, but Simvastatin's established safety profile as a cholesterol-lowering agent may provide a unique advantage. The trial's outcomes could influence market dynamics, particularly if they demonstrate a clear benefit over existing treatments. Diligence should focus on the trial's recruitment status and any emerging data that may affect market entry timelines.
Indication: Mild Cognitive Impairment
Modality: small molecule
Target: Amyloid production in the brain related to Alzheimer's dementia.
Sponsor: Charite University, Berlin, Germany
Source URL: ClinicalTrials.gov
Source updated: Jan 27, 2020
Ingested: Jun 13, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Amyloid production in the brain related to Alzheimer's dementia.
View original source fields
Condition raw: Mild Cognitive Impairment
Condition normalized: Mild Cognitive Impairment
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Amyloid production in the brain related to Alzheimer's dementia.
Target normalized: Amyloid production in the brain related to Alzheimer's dementia.